Gilead Science’s hepatitis B drug Vemlidy gets expanded insurance benefit

Korea Biomedical Review

2 May 2022 - Gilead Science Korea said its hepatitis B treatment Vemlidy (tenofovir alafenamide) started receiving expanded health insurance coverage for treating patients with decompensated cirrhosis and hepatitis B with hepatocellular carcinoma on Sunday.

The government expanded the reimbursement standard following the change in the detailed recognition standards for medical care benefits for oral chronic hepatitis B treatment.

Read Korea Biomedical Review article 

Michael Wonder

Posted by:

Michael Wonder